The Hutchinson-Gilford Progeria Syndrome Market is set for strong growth (2025-2035) with rising research in rare genetic disorders, precision medicine, and innovative therapies. Driven by gene therapy, FTIs, and global collaborations, the market could reach USD 261.9M by 2035, transforming care for this rare, fatal childhood condition. Get More Info:- https://www.futuremarketinsights.com/reports/hutchinson-gilford-progeria-syndrome-hgps-therapeutics-market

Cell and Gene Therapy Market Expected to Surge from $24.6B in 2024 to $166.9B by 2034 The Cell and Gene Therapy Market Size is forecasted to be valued at US$ 166.9 billion by 2034 from US$ 24.6 billion in 2024, growing at a CAGR of 21.1% during the forecast period 2025 to 2034. North America held a dominant market position, capturing more than a 47.8% share and holds US$ 11.8 Billion market value for the year. https://market.us/report/cell-and-gene-therapy-market/

UN'ALTRA BUONA NOTIZIA! ‼️Gli USA fermano i finanziamenti a GAVI, che è l’associazione per promuovere le vaccinazioni in tutto il mondo. GAVI attualmente è presieduto da Josè Manuel Barroso che era il presidente della Commissione Europea, quando questa nel 2009 ha - su pressione dell’industria farmaceutica - deciso di escludere dalla categoria dei prodotti di terapia genica sostanze solo formalmente definite “vaccini contro infezioni virali”- a prescindere dalla loro effettiva composizione e dal loro effettivo meccanismo d’azione analogo a quello dei prodotti di terapia genica. Così, Josè Manuel Barroso - su richiesta dell’industria farmaceutica - ha posto le basi regolamentari criminali per portare sul mercato ai fini dell’uso in massa nell’ambito di campagne “vaccinali” sostanze sperimentali a base genetica. Barroso & Co. sono dei criminali, ai quali bisogna fare il processo, e soprattutto non consentire di decidere la politica sanitaria del nostro paese con cosiddette “Agende di immunizzazione”! Un primo importante passo degli USA, ma non basta! Barroso & Co. devono pagare per quello che hanno commesso e continuano a commettere, e cioè per le stragi a livello mondiale di cui sono responsabili! ANOTHER GOOD NEWS! ‼️The USA stops funding GAVI, which is the organization aimed at promoting vaccinations worldwide. GAVI is currently chaired by Josè Manuel Barroso, who was the president of the European Commission when, in 2009, under pressure from the pharmaceutical industry, it decided to exclude substances formally defined as 'vaccines against viral infections' from the category of gene therapy products - regardless of their actual composition and their actual mechanism of action similar to that of gene therapy products. Thus, Josè Manuel Barroso - at the request of the pharmaceutical industry - laid the criminal regulatory foundations to bring experimental genetic-based substances to market for mass use in 'vaccination' campaigns. Barroso & Co. are criminals who must be prosecuted, and above all, should not be allowed to decide the health policy of our country with so-called 'Immunization Agendas'! A first important step from the USA, but it's not enough! Barroso & Co. must pay for what they have committed and continue to commit, namely for the global massacres they are responsible for!

‼️Presentato in Tribunale dell’Unione Europea ricorso di annullamento dell’autorizzazione della sostanza sperimentale altamente pericolosa KOSTAIVE-Zapomeran, basata sull’RNA autoamplificante, con richiesta di provvedimento cautelare. MASSIMA DIFFUSIONE! Il 9 giugno 2025, nella mia funzione istituzionale di membro del Consiglio Provinciale del Sudtirolo/Alto Adige, ho presentato al Tribunale dell’Unione Europea un ricorso di annullamento ai sensi dell’articolo 263 TFUE contro la decisione della Commissione europea del 12 febbraio 2025 con cui è stata autorizzata come “vaccino”-Covid-19 la sostanza sperimentale KOSTAIVE-Zapomeran, basata sull’ingegneria genetica e costituita da RNA auto-amplificante. L’autorizzazione di KOSTAIVE è stata concessa senza che fossero stati effettuati studi essenziali per le sostanze basate sull’ingegneria genetica. Per KOSTAIVE non sono stati studiati né esclusi la genotossicità, la carcinogenicità, la mutagenicità (alterazione del DNA), né la trasmissibilità all’ambiente. Ciò è stato possibile perché nel 2009 la Commissione europea, sotto la presidenza di Josè Emanuel Barroso, ha escluso le sostanze dichiarate formalmente come “vaccini contro le malattie infettive” dall’applicazione delle severe norme di autorizzazione previste per i prodotti di terapia genica, a seguito dell’intervento dell’industria farmaceutica. I dettagli e i documenti relativi a questo procedimento criminale sono contenuti nel ricorso di annullamento. Non sorprende, quindi, che l’allora presidente della Commissione europea Barroso sia ora i CEO dell’alleanza per i vaccini GAVI e quindi il massimo lobbista dell’industria dei vaccini. Il KOSTAIVE comporta gravi rischi per la salute e la vita della popolazione dell’UE. Già dal foglietto illustrativo emerge che esiste il rischio di miocardite e pericardite. Esperti in posizioni istituzionali, come il direttore del Centro Nazionale per la Salute Globale presso l’Istituto Superiore di Sanità, temono che l’RNA auto-amplificante di KOSTAIVE possa essere trasmesso attraverso vescicole extracellulari (EV) all’intero ambiente, e dunque anche alle persone non trattate con KOSTAIVE e a tutti gli animali (le EV non conoscono barriere di specie). Il rispettivo articolo scientifico pubblicato dal dott. Maurizio Federico (e finanziato dal Ministero della Salute) è stato allegato come doc. 6 al ricorso di annullamento. Pertanto, il principio della necessità del libero consenso al trattamento farmacologico, sancito dal diritto internazionale, dal diritto dell’Unione Europea e dalle Carte Costituzionali degli Stati membri dell’Unione Europea, è stato di fatto abolito dalla Commissione Europea con l’autorizzazione di questa pericolosa sostanza sperimentale geneticamente modificata con rilevanza penale! I motivi per cui in questo caso ogni singolo cittadino dell’UE ha la legittimazione ad agire dinanzi al Tribunale europeo sono riportati in dettaglio nel ricorso di annullamento. Data l’estrema urgenza della questione (è in gioco la salute e la vita di tutti i cittadini dell’UE!), è stata presentata anche un’istanza di provvedimento cautelare e la richiesta per l’adozione del procedimento accelerato. I cittadini dell’UE, rappresentati da avvocati, possono partecipare al procedimento, che pende con T-375/27, in qualità di intervenienti. ‼️Lawsuit Filed at the European Union Court to Annul Authorization of the Highly Dangerous Experimental Substance KOSTAIVE-Zapomeran, Based on Self-Amplifying RNA, with Request for Interim Measures On June 9, 2025, in my official capacity as a member of the Provincial Council of South Tyrol/Alto Adige, I filed an annulment lawsuit under Article 263 TFEU at the Court of Justice of the European Union against the European Commission’s decision of February 12, 2025, which authorized the experimental substance KOSTAIVE-Zapomeran—a genetically engineered, self-amplifying RNA-based product—as a "Covid-19 vaccine." The authorization of KOSTAIVE was granted **without conducting essential studies required for genetically engineered substances. For **KOSTAIVE, genotoxicity, carcinogenicity, mutagenicity (DNA alteration), and environmental transmission were neither studied nor ruled out. This was possible because, in 2009, under the presidency of José Manuel Barroso, the European Commission excluded substances formally declared as "vaccines against infectious diseases" from the strict authorization rules applied to gene therapy products, following pressure from the pharmaceutical industry. The details and documents regarding this criminal proceeding are included in the annulment lawsuit. Unsurprisingly, the former European Commission President Barroso is now the CEO of the vaccine alliance GAVI and thus the top lobbyist for the vaccine industry. KOSTAIVE poses serious risks to the health and lives of EU citizens. Even the package leaflet acknowledges the risk of myocarditis and pericarditis. Experts in institutional positions, such as the Director of the National Center for Global Health at the Italian National Health Institute (Istituto Superiore di Sanità), fear that the self-amplifying RNA in KOSTAIVE could be transmitted through extracellular vesicles (EVs) to the entire environment, including people not treated with KOSTAIVE and all animals (since EVs do not respect species barriers). The scientific article published by Dr. Maurizio Federico (and funded by the Italian Ministry of Health) was attached as Document 6 to the annulment lawsuit. Thus, the principle of free and informed consent to medical treatment, enshrined in international law, EU law, and the constitutions of EU member states, has been effectively abolished by the European Commission** through the authorization of this dangerous, genetically modified experimental substance, which carries potential criminal liability! The reasons why every single EU citizen has standing to bring this case before the European Court are detailed in the annulment lawsuit. Given the extreme urgency of the matter (the health and lives of all EU citizens are at stake!), a request for interim measures and an expedited procedure has also been filed. EU citizens, represented by lawyers, can join the proceedings (Case T-375/27) as interveners. https://www.renate-holzeisen.eu/it/presentato-ricorso-di-annullamento-dellautorizzazione-come-vaccino-della-sostanza-sperimentale-kostaive-zapomeran-con-istanza-cautelare/?amp=1

The global bleeding disorders market is witnessing substantial growth as awareness about rare medical conditions continues to rise and advancements in diagnostics and treatment solutions progress. With a greater focus on improving healthcare infrastructure, alongside increased investment in medical research, the market for bleeding disorders is expected to expand rapidly in the coming years. Bleeding disorders are a group of conditions that prevent blood from clotting properly, leading to prolonged bleeding. These disorders are classified into various categories, with the most common being hemophilia A, hemophilia B, von Willebrand disease, and platelet function disorders. The growth of the bleeding disorders market is driven by an aging population, the rise in cases of hemophilia and other clotting factor deficiencies, and an increase in demand for personalized therapies. Market Overview: The global bleeding disorders market size is expected to reach USD 27.49 billion by 2032, according to a new study by Polaris Market Research. With advancements in medical treatments, the prognosis for individuals with bleeding disorders has improved, but challenges such as high treatment costs, limited access to care in developing regions, and the need for more innovative therapies remain. The bleeding disorders market is driven by advancements in genetic therapies, biologics, and innovative clotting factor concentrates. Hemophilia remains the most prevalent condition, especially among males, which has resulted in a growing demand for products that can help with disease management. As the healthcare industry focuses on rare diseases and orphan drug therapies, the bleeding disorders market is on the cusp of significant transformation. Key Market Growth Drivers: Increasing Awareness and Diagnosis: With a growing focus on genetic testing and early diagnosis, many previously undiagnosed cases of bleeding disorders are being identified. This helps in early intervention and reduces complications associated with the disorder. Efforts by nonprofit organizations and medical societies are crucial in increasing awareness among the general population and healthcare professionals. Advancements in Gene Therapy: Gene therapy has emerged as a groundbreaking treatment for bleeding disorders, particularly hemophilia. By introducing functional copies of the missing clotting factor genes, gene therapy holds the promise of long-term or even permanent relief from symptoms. This therapy has the potential to significantly reduce or eliminate the need for regular factor infusion treatments, transforming the treatment landscape. Development of Novel Treatments: The market is seeing a rise in novel treatment options that provide better efficacy and convenience for patients. New treatments, including extended half-life clotting factor concentrates and non-factor therapies like emicizumab, have improved the quality of life for individuals with bleeding disorders. These innovations also promise fewer treatment burdens, offering hope for better disease management. Rising Prevalence of Bleeding Disorders: An increase in the number of cases of hemophilia, von Willebrand disease, and other bleeding disorders is contributing to market growth. As the global population ages, the number of individuals affected by these conditions is expected to rise, particularly in regions where healthcare access is limited. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/bleeding-disorders-market Challenges in the Bleeding Disorders Market: High Treatment Costs: The cost of treatment for bleeding disorders, especially hemophilia, is a major barrier to access for many patients worldwide. Factor replacement therapies, which are commonly used to prevent bleeding episodes, are expensive, and their high cost often poses a financial burden on healthcare systems, particularly in low and middle-income countries. Limited Access to Treatment in Developing Regions: While bleeding disorders are globally recognized, access to treatment remains limited in many developing countries. Lack of awareness, infrastructure, and skilled healthcare personnel poses a significant challenge to the early diagnosis and treatment of bleeding disorders. Efforts to provide affordable treatments and expand healthcare access are crucial to improving outcomes in these regions. Adverse Reactions and Complications: Despite the advancements in treatments, adverse reactions, such as immune responses to clotting factor concentrates, can complicate disease management. The development of inhibitors (antibodies that neutralize the clotting factor) further complicates treatment and requires alternative therapies, which are often more expensive. Lack of Universal Screening and Diagnosis: Early diagnosis of bleeding disorders is critical to successful treatment, but many individuals are not diagnosed early enough to benefit from the full range of available therapies. Genetic testing and screening initiatives are crucial to addressing this issue, especially in areas where awareness and healthcare access are limited. Regional Analysis: The global bleeding disorders market is segmented into several key regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America: North America holds the largest share of the bleeding disorders market, driven by advanced healthcare systems, a high prevalence of hemophilia, and substantial investments in research and development. The presence of leading pharmaceutical and biotechnology companies in the region further fuels market growth. The United States, in particular, is a major player, with significant market demand for hemophilia treatments and advanced therapies. Europe: Europe represents a significant share of the market due to the increasing number of hemophilia patients, improved healthcare infrastructure, and supportive government policies for rare disease treatments. European countries like Germany, the UK, and France are leading the way in implementing comprehensive healthcare programs to manage bleeding disorders effectively. Asia-Pacific: The Asia-Pacific region is witnessing rapid growth in the bleeding disorders market due to increased awareness, rising healthcare expenditure, and improving infrastructure. Countries like China and India are seeing a rise in the diagnosis of hemophilia, creating new opportunities for market players. However, the region still faces challenges related to treatment affordability and access to care in rural areas. Latin America: Latin America’s market for bleeding disorders is growing as awareness increases and healthcare systems improve. However, the region faces challenges such as the high cost of treatment and the need for further improvements in diagnostic and treatment infrastructure. Middle East & Africa: The Middle East and Africa present a smaller but rapidly developing market for bleeding disorders. The region is characterized by significant unmet medical needs and limited access to specialized treatments, which presents an opportunity for growth. Government initiatives to improve healthcare access are expected to drive market expansion in these areas. Key Companies in the Bleeding Disorders Market: Several leading companies are at the forefront of developing innovative therapies for bleeding disorders. These include: Baxter International: A key player in the bleeding disorders market, Baxter is known for its advancements in hemophilia treatments, including clotting factor products and extended half-life therapies. Baxter continues to lead the way in providing high-quality products to individuals with bleeding disorders globally. Novo Nordisk: Novo Nordisk is a major provider of hemophilia therapies, offering a range of products designed to manage bleeding episodes. The company’s commitment to research and development is helping drive advancements in hemophilia treatment options. Pfizer: Pfizer has made significant strides in the bleeding disorders market, particularly with its novel therapies like emicizumab, which has revolutionized the treatment of hemophilia. Pfizer’s innovative therapies are setting new standards in the management of bleeding disorders. Sanofi: Sanofi is a leader in the bleeding disorders market, with a focus on hemophilia treatment options. Their therapies have been recognized for their ability to improve patient outcomes and enhance the quality of life for those with bleeding disorders. Grifols: Grifols is a global biotechnology company that specializes in blood plasma products. The company’s expertise in hemophilia treatments and clotting factor concentrates has made it an essential player in the market. Conclusion: The bleeding disorders market is poised for significant growth as healthcare systems across the globe continue to evolve, and treatment options become more advanced and accessible. While challenges such as high treatment costs and limited access to care remain, the market is driven by advancements in gene therapy, innovative treatments, and rising awareness. With an increasing number of patients being diagnosed and new therapies on the horizon, the future of the bleeding disorders market looks promising, offering hope for improved outcomes and better quality of life for individuals living with these conditions. More Trending Latest Reports By Polaris Market Research: Cloud ERP Market Specialty Gas Market Single Use Assemblies Market Hernia Repair Market Gamma Decalactone Market Benzene Market Digital Content Creation Market Biotechnology and Pharmaceutical Services Outsourcing Market Healthcare Supply Chain Management Market

What is the outlook for the biotechnology industry? The outlook for the biotechnology industry is one of cautious optimism, with promising growth on the horizon as it continues to address pressing global challenges in health, agriculture, and sustainability. In 2024, the global biotech market was valued at USD 761.5 billion, and it is expected to expand to USD 1,315.9 billion by 2033, driven by a robust compound annual growth rate (CAGR) of approximately 6.27% from 2025 to 2033. This positive trajectory reflects advancements in fields like gene therapy, biopharmaceuticals, and bio-based materials, supported by increased funding and technological innovation. Despite potential hurdles such as regulatory complexities and economic fluctuations, the industry’s steady progress signals a resilient and transformative future through the next decade. Read the full report here: https://www.imarcgroup.com/biotechnology-market #marketresearch #business #marketanalysis #markettrends #researchreport #marketreport #marketforecast #marketanalysis #marketgrowth #imarcgroup

💉 1700% increase in Athlete Cardiac arrests. Remember this wasn’t happening to Athletes during Delta Wave (the most allegedly virulent BS variant), only post mRNA experimental Gene Therapy Jab did we start witnessing this phenomenon. It should be pretty obvious what’s causing it, NPC’s will claim it’s always happened…….it hasn’t. Russel Brand asks the question as to why MSM don’t even bother to ask any questions around it? Greatest Crime Against Humanity EVER. 💉 Aumento del 1700% degli arresti cardiaci degli atleti. Ricorda che questo non stava accadendo agli atleti durante l'Onda Delta (la variante presumibilmente più virulenta di BS), solo dopo il Jab sperimentale di terapia genica con mRNA abbiamo iniziato a testimoniare questo fenomeno. Dovrebbe essere abbastanza ovvio cosa lo sta causando, gli NPC affermeranno che è sempre successo… non è così. Russel Brand si chiede perché gli MSM non si preoccupano nemmeno di fare domande al riguardo? Il più grande crimine contro l’umanità di SEMPRE.

QUESTA DENUNCIA contro i moderni vaccini a mRNA, che tante morti improvvise e gravi danni stanno provocando, va fatta girare! I "vaccini" modRNA e DNA contro SARS-CoV-2, che non sono vaccini ma terapie geniche, trasformano letteralmente i tuoi organi (o parti dei) tuoi organi in "organi trapiantati" che vengono rifiutati dal tuo sistema immunitario. Grazie alla comprovata contaminazione con DNA batterico funzionale possono farlo per anni e forse anche per tutta la vita. E c'è un rischio considerevole che tu trasmetta questa terapia genica alla tua prole. "Attualmente l'industria farmaceutica sta lavorando per trasferire tutte le vaccinazioni sulla piattaforma modRNA “vaccine”. Lo sta facendo, anche se basta saper contare e distinguere l'estraneo dall'auto, pur avendo una traccia di intelligenza, per rendersi conto che la piattaforma del vaccino modRNA è totalmente priva di senso e pericolosa per la vita. I suoi due difetti fondamentali sono l'iniezione del piano di costruzione di una proteina estranea al corpo senza avere alcun controllo su quali cellule del corpo la produrranno, in quale dose e per quanto tempo, e il fatto che le cellule costrette a produrre questa proteina estranea e poi a presentarla sulla loro superficie saranno erroneamente riconosciute dal nostro sistema immunitario come estranee, quindi distrutte, proprio come il rigetto di un organo estraneo trapiantato in te. La "vaccinazione" costringe il tuo corpo a produrre una tossina in dosi sconosciute e per un periodo di tempo sconosciuto e trasforma letteralmente parti di te in un alieno. Pertanto, l'intera piattaforma del vaccino modRNA deve essere bandita immediatamente!" The modRNA and DNA "vaccines" against SARS-CoV-2, which are no vaccines but gene therapies, literally turn (parts of) your organs into "transplanted organs" that are rejected by your immune system. By the proven contamination with functional bacterial DNA they can do this for years and maybe even for your whole life. And there is a considerable risk that you even hand down this gene therapy to your offspring. "Currently, the pharmaceutical industry is working on transferring all vaccinations to the modRNA “vaccine” platform. It is doing so, though just being able to count and to distinguish foreign from self, even having a trace of intelligence, is enough to realise that the modRNA vaccine platform is totally nonsensical and life-threatening. Its two fundamental flaws are the injection of the construction plan for a protein foreign to the body without having any control over which body cells will produce it, in what dose and for how long, and the fact that the cells who are coerced to produce this foreign protein and then present it on their surface will be mistakenly recognised by our immune system as foreign, thus destroyed, much like the rejection of a foreign organ transplanted into you. The alleged modRNA "vaccination" coerces your body to produce a toxin in unknown dose and for an unknown period of time and literally transforms parts of you into an alien. Therefore, the entire modRNA vaccine platform must be banned immediately!" https://twitter.com/Thomas_Binder/status/1675729943873966080?s=20